While the broad-based S&P 500 Index is showing a modest gain of just 2.2% so far this year, a handful of this year's top penny stocks are boasting gains as much as 110%.
Two recently signed deals to be acquired, one just inked a deal with a major pharmaceutical company, and one is close to approval on a cancer therapy